Synageva BioPharma is a privately held biopharmaceutical company dedicated to discovering, developing and delivering therapies for patients with rare conditions and unmet medical need. Its lead program is SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, and the company has initiated global clinical studies for SBC-102. The pipeline also includes two enzyme replacement therapies for Lysosomal Storage Disorders and two non-LSD programs for life‑threatening conditions. Synageva is expanding its network of physicians and medical professionals to support development and commercialization efforts. Management states the company can make these products at commercial scale and emphasizes its team’s rare disease expertise. Financially, Synageva announced a $25 million private equity financing and has secured $70 million in funding over the last two and a half years. The company is based in Lexington, Mass. Synageva BioPharma is dedicated to developing and commercializing novel, next‑generation and follow‑on protein therapeutics leveraging its proprietary Synageva Expression Platform (SEP). The company is focused on building a portfolio of innovative medicines for patients with rare diseases and high unmet medical need. Synageva is based in Waltham, MA and Athens, GA. It completed a $45M financing, which the company says will help realize its vision and advance its clinical and development programs. As part of the financing New Leaf Venture Partners joined the investor group and its managing director, Srini Akkaraju, M.D., Ph.D., will join Synageva’s board. Synageva also expanded its senior leadership team with multiple key appointments across medical, government and business affairs, strategic development, quality and regulatory affairs, and business development.

Total raised

$70M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2011